COST-EFFECTIVENESS ANALYSIS OF ROTAVIRUS VACCINATION IN CHILDREN UNDER FIVE YEARS OLD IN MOROCCO

Youness Lagoubi,¹ Amadou Barry,¹ <u>Mohammed Bouskraoui</u>,² Jorge A. Gomez,³ Ahmed Mohy⁴

¹GSK, Casablanca, Morocco, ²Cadi Ayyad University, Marrakech, Morocco, ³GSK, Buenos Aires, Argentina, ⁴GSK, Wavre, Belgium

Background



Rotavirus vaccination was introduced into the Moroccan National Immunization Program (NIP) in 2010 to control severe and fatal rotavirus gastroenteritis (RVGE) in children¹



Objective: To compare **total vaccination costs** and the **cost-effectiveness**, from payer and societal perspectives, of implementing three different rotavirus vaccines into the Moroccan NIP for the 2022 birth cohort using a **health-economic analysis**

Methods

Two types of evaluations were reported in the health economic model:

Vaccines Included

Oral live attenuatedLive, oral,human rotavirus vaccinerotaviru(RIX4414; GSK, Belgium)(PRV; M

Live, oral, pentavalent Ro rotavirus vaccine (PRV; Merck, USA) (RVL

Cost Components Included in the Cost Analysis and

Rotavirus vaccine, live attenuated oral (freeze-dried) 1-dose (RVLA-1; Serum Institute of India, India)

- Cost analysis: the costs of two or more vaccines were compared; consequences or outcomes of the vaccines were not considered
- 2. Cost-effectiveness analysis: a full economic evaluation, which compares two or more vaccines in terms of their costs and outcomes

Form	Liquid (plastic tube)	Liquid (plastic tube)	Lyophilised powder (2-vial set)
No. doses per fully immunised child	2	3	3
Purchase price (per dose)	\$6.50 ²	\$5.20 ³	\$3.00 ²
No. vials/tubes per carton	50	25	50 active and 50 diluent
No. doses per vial	1	1	1
Storage volume (cm ³)	17.12	46.25	35.14

Cost-Effectiveness Model Flow Diagram

Step A: Natural disease module

Natural Disease	• A	
ModuleCosts:Clinical (QALYs/DALYs):• Home care treatment• RVGE treated at home• Medical visits• RVGE requiring medical visits• Medical visits• RVGE requiring hospitalisations• Hospitalisations• RVGE deaths• Direct non-medical costs• RVGE deaths• Productivity losses• Sees	P (v a W S	

Step B: Natural disease module + intervention control system

Intervention Natural Disease		
Control System Module Feedback loop of the control system in place	 Home care RVGE treatment Medical visits Hospitalisations Direct RVGE red RVGE deal 	cts of vaccination f side-effects of

Cost-Effectiveness Analysis Cost-Effectiveness Analysis **Cost Analysis** Analysis Societal (country Societal (country Country Country Perspective payer + caregiver) payer payer + caregiver) payer Vaccination costs (waste adjusted vaccine Yes Yes Yes Yes acquisition, vaccine administration, waste disposal) Supply chain costs (International Yes Yes Yes Yes transportation/handling and local storage/transportation) **Caregiver attending costs** Yes Yes No No (transportation to receive vaccine^a) **RVGE** management costs Yes (homecare, medical visits, No No Yes hospitalisation) **Direct non-medical costs** No No No Yes (transportation to manage RVGE)

costs
 Side-effects of vaccination

Productivity losses of caregivers
to manage RVGENoNoNoYes^aCaregiver attendance cost was estimated based on the conservative assumption of distributing the cost between the vaccine


^aCaregiver attendance cost was estimated based on the conservative assumption of distributing the cost between the vaccines given together at the same session

Components derived from the intervention control system are highlighted in orange


Main Cost-Effectiveness Analysis Assumptions


- Vaccine efficacy (VE) was assumed equal (41.5%)¹ for all 3 vaccines in complete schedule and for all 4 RVGE health states; homecare, medical visits, hospitalisation and death
- VE decrements were applied due to missing subsequent doses; 10.0% relative VE reduction between first and second dose of the 2-dose vaccine; 2.4% (between first and second dose) and 13.6% (between second and third dose) for 3-dose vaccines⁴

Vaccine Coverage Estimates



^aWHO and UNICEF estimates of immunization coverage of DTP1 (2021); ^bAssumed equal coverage to first dose; ^cMorocco Ministry of Health records (on file)









The **2-dose vaccine** was associated with **fewer RVGE cases** compared with **3-dose vaccines**; **-284** homecare, **-84** medical visits; and **-12** hospitalisations

RVGE cases avoided translated into **10 QALYs** (discounted) gained for RIX4414 (1,679 discounted QALYs) compared with PRV (1,689 discounted QALYs) and RVLA-1 (1,689 discounted QALYs) over the model time horizon

	Discounted ICER	
Vaccine comparisons	RIX4414 vs. PRV	RIX4414 vs. RVLA-1
Country payer perspective	RIX4414 was dominant	\$258,872
Societal perspective (country payer + caregiver)	RIX4414 was dominant	RIX4414 was dominant
'Dominant' demonstrates higher benefit at lower cost		

Conclusion

The 2-dose rotavirus vaccine was demonstrated to be a cost-saving option compared with 3-dose vaccines, especially when societal costs were considered

Abbreviations: DALY: disability adjusted life year; ICER: incremental cost-effectiveness ratio; NIP: National Immunization Programme; PRV: Live, oral, pentavalent rotavirus vaccine; QALY: quality-adjusted life year; RIX4414: Oral live attenuated human rotavirus vaccine; RVGE: rotavirus gastroenteritis; RVLA-1: Rotavirus vaccine, live attenuated oral (freeze-dried) 1-dose; UNICEF: United Nations Children's Fund; VE: vaccine efficacy; WHO: World Health Organization. **References:** 1. Benhafid M et al. J Med Virol 2015;87:944–53; 2. PAHO Revolving Fund Prices. 2021. https://www.paho.org/en/revolvingfund [Accessed 18 May 2022]; 3. Loganathan T et al. Health Policy Plan. 2018;33(2):204–214; 4. Tilson L et al. Vaccine. 2011;29:7463–73. 5. Le Maroc en chiffres 2019. 2019. 58th edition. Accessible from https://www.hcp.ma/ [Accessed 18 May 2022] **Acknowledgements:** The study reported was funded by GlaxoSmithKline Biologicals SA. The authors acknowledge Bella Dragova-Maurin, GSK, for publication management. The authors also thank Costello Medical for editorial assistance and publication coordination, on behalf of GSK, and acknowledge Samuel Shields and Megan Thomas, Costello Medical, UK for medical writing and editorial assistance based on authors' input and direction. **Disclosures:** The economic evaluation was conducted by adapting a GSK-sponsored health economic model. **AB** is an employee of GSK. **YL**, **JG** and **AM** are employees and shareholders of GSK. **MB** received consultation fees from GSK for this study.